2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Serologic Tests, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, Research, Translational Research, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3968 A phase 2 trial of anti-B-cell maturation antigen/CD3 bispecific antibody gamgertamig in patients with relapsed/refractory systemic light chain amyloidosis

Gang An, MD, Kaini Shen, MD2, Jie Ma3, Peilong Lai, PhD4, Hui-Han Wang5, Yu Wu6, Liye Zhong, MD, PhD7, Zhen Cai8, Pengcheng He9, Hongling Peng, MD, PhD10, Mingxia Shi11, Weijun Fu12, Yongqiang Wei13, Chunrui Li, PhD14, Fei Li, MD, PhD15, Jun Luo16, Chunyan Sun, MD17, Weiwei Tian, MD, PhD18, Hongbin Zhang19, Jian Li, MD20
1 Chinese Academy of Medical Sciences & Blood Disease Hospital, Tianjin, China
2 Peking Union Medical College Hospital (PUMCH), Beijing, China
3 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
4 Guangdong Provincial People's Hospital, Guangzhou, China
5 Shengjing Hospital of China Medical University, Shenyang, China
6 West China Hospital of Sichuan University, Chengdu, China
7 The First Affiliated Hospital of Jinan University, Guangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
10 The Second Xiangya Hospital of Central South University, Changsha, China
11 The First Affiliated Hospital of Kunming Medical University, Kunming, China
12 Shanghai Fourth People's Hospital, Shanghai, China
13 Nanfang Hospital, Southern Medical University, Guangzhou, China
14 Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China
15 The First Affiliated Hospital of Nanchang University, Nanchang, China
16 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
17 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
18 The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, China
19 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
20 Peking Union Medical College Hospital (PUMCH), Beijing, China

Introduction: Systemic light chain amyloidosis (SLCA) is a fatal clonal plasma cell disorder characterized by deposition of misfolded monoclonal immunoglobulin light chains in organs, leading to muti-organ dysfunction. Achievement of rapid and deep normalization of the involved free light chain (iFLC) is associated with improved organ recovery and survival, but treatment options for relapsed/refractory disease remain limited. Gamgertamig is an independently developed innovative subcutaneously administered bispecific T-cell engager. Here we present the preliminary efficacy and safety data of gamgertamig monotherapy in patients (pts) with relapsed/refractory SLCA in an ongoing open-label, randomized, phase 2 trial (NCT07039578).

Methods: Eligible pts (18 years or older) had ECOG 0-2, had ≥1 involved organ, had a difference between involved and uninvolved serum free light chain (dFLC) of ≥20 mg/L, and had received ≥1 prior line of therapy (including both bortezomib and anti-CD38 monoclonal antibody) with no prior BCMA exposure. In Part 1, the first 20 pts with Mayo 2004 stage I-IIIa relapsed/refractory SLCA were randomized to receive subcutaneous gamgertamig at either 80 mg or 160 mg with step-up dosing for up to 2 years. Following completion of the randomized phase, all subsequent enrolled pts received gamgertamig 160 mg. Gamgertamig was administered weekly initially, with dosing intervals extended to every 2 weeks (Q2W), Q4W, or Q8W based on treatment response. Efficacy endpoints included hematologic response, organ response, and time to response. Safety was also assessed.

Results: As of July 10, 2026, a total of 37 pts (median age, 63 years [range 37-75]) received gamgertamig 80 mg (n=10) or 160 mg (n=27). Pts had received a median of 2 prior lines of therapies (range 1-10), and the median time since diagnosis was 3.0 years (range 0.3-11.5). The median baseline dFLC was 93.5 mg/L (range 23.4-933.0) and serum M-protein was 0.8 g/L (range 0.0-21.6). At baseline, cardiac, renal, and hepatic involvement was present in 70.3%, 43.2%, and 10.80% of pts, respectively, and 59.5% had AL-lambda amyloidosis.

As patients enrolled after the randomized phase had limited follow-up, this preliminary analysis presents efficacy data only for the 20 patients in the randomized phase; comprehensive long-term follow-up data from the entire study will be added at the time of presentation. At a median follow-up of 6.7 months (range 2.1-11.4), 90.0% of pts continued treatment. The hematologic objective response rate (hORR) was 100%; 95.0% of pts achieved a hematologic very good partial response (hVGPR) or better and 90.0% achieved a hematologic complete response (hCR). The median time to hCR was 0.9 months (range 0.2-4.5). All pts achieved iFLC <20 mg/L and dFLC <10 mg/L, with a median time to response of 0.5 months (range 0.2-1.1). Among the 17 measurable residual disease (MRD)-evaluable pts, 100% achieved MRD negativity at 10−5. No pts experienced hematologic progression. 10/13 (76.9%) pts achieved cardiac ORR and 9 (100.0%) achieved renal ORR.

All 37 pts experienced treatment-emergent adverse events (TEAEs). The most common TEAEs were haematological toxicities, hypogammaglobulinemia, infections, and cytokine release syndrome (CRS). Infections occurred in 64.9% of pts, most commonly upper respiratory tract infection (37.8%). CRS occurred in 37.8% of pts, with only two grade 2 events (5.4%) and no grade ≥3 events. The median time to onset from last gamgertamig administration was 32.8 hours, and the median duration was 11.5 hours. No immune effector cell-associated neurotoxicity syndrome occurred. No TEAEs leading to treatment discontinuation occurred.

Conclusions: Gamgertamig monotherapy had a manageable safety profile and induced rapid and deep hematologic and organ responses in adults with relapsed/refractory SLCA. These results support continued clinical evaluation of gamgertamig in this patient population.
Kaini Shen, MD: No relevant conflicts of interest to declare.